EU Horizon funding · NACE 21
Horizon Europe funding for pharmaceutical companies
NACE 21 · Manufacture of basic pharmaceutical products and pharmaceutical preparations
38 pharmaceutical companies (NACE 21) received €72M in EU research and innovation funding across 111 Horizon Europe and Horizon 2020 projects starting between 2014 and 2027; 31% of the money went to SMEs.
- EU contribution
- €72M
- 2014–2027 project starts
- Funded companies
- 38
- 18 of them SMEs
- Projects
- 111
- Horizon Europe and Horizon 2020
- Share to SMEs
- 31%
- €23M to SMEs
Industry is known only for companies matched to the national business registers in France, Finland, Belgium, Estonia, Sweden and Czech Republic, so this page covers funded private companies from those countries. Companies elsewhere in Europe are counted on the country pages.
In numbers
Pharmaceutical companies (NACE 21) rank 18th of 62 industry divisions by total EU funding received.
Of the total, Horizon 2020 (2014–2020) accounts for €40M across 62 projects and Horizon Europe (2021–2027) for €32M across 49 projects.
The strongest start year was 2014, when projects worth €14M to these companies began.
The largest funding route was the Research and Innovation Action (RIA) with €38M (53% of the total, 44 projects). The SME Instrument Phase 2 added €5M for 1 project.
AstraZeneca AB (Södertälje) is the largest recipient with €15M over 37 projects; the 10 largest recipients together received 87% of the total.
The average funded company received €1.9M; 47% of the companies are SMEs.
By programme
Horizon 2020 2014–2020
€40M
62 projects · 56% of the total
Horizon Europe 2021–2027
€32M
49 projects · 44% of the total
Funding by start year
EU contribution to these companies, by the year their project started.
| Year | EU contribution |
|---|---|
| 2014 |
€14M
|
| 2015 |
€6.5M
|
| 2016 |
€2.7M
|
| 2017 |
€3.3M
|
| 2018 |
€1.2M
|
| 2019 |
€4.7M
|
| 2020 |
€3M
|
| 2021 |
€6.8M
|
| 2022 |
€4.8M
|
| 2023 |
€8.3M
|
| 2024 |
€2.1M
|
| 2025 |
€4M
|
| 2026 |
€9.6M
|
| 2027 |
€325k
|
2014–2020 starts (mostly Horizon 2020) 2021 onwards (Horizon Europe)
Largest recipients
Companies with the highest EU contribution, Horizon Europe and Horizon 2020 combined.
| # | Company | Programmes | Projects | EU contribution |
|---|---|---|---|---|
| 1 | AstraZeneca AB Södertälje, Sweden | Horizon 2020, Horizon Europe | 37 | €15M |
| 2 | GlaxoSmithKline Biologicals Rixensart, Belgium | Horizon 2020 | 1 | €14M |
| 3 | Janssen Pharmaceutica Beerse, Belgium | Horizon 2020, Horizon Europe | 27 | €9.5M |
| 4 | NorthX Biologics AB SME Matfors, Sweden | Horizon 2020, Horizon Europe | 3 | €8.5M |
| 5 | Firalis Molecular Precision SME Huningue, France | Horizon 2020 | 1 | €5M |
| 6 | Perseus Biomics SME Leuven, Belgium | Horizon Europe | 2 | €3.2M |
| 7 | Quantoom Biosciences Nivelles, Belgium | Horizon Europe | 3 | €2.8M |
| 8 | Inteliphage SME Ottignies-Louvain-la-Neuve, Belgium | Horizon Europe | 1 | €1.8M |
| 9 | Obulytix Gent, Belgium | Horizon Europe | 1 | €1.5M |
| 10 | Adhexpharma Paris, France | Horizon 2020, Horizon Europe | 2 | €1.2M |
Funding schemes
How the money reached these companies.
-
Research and Innovation Action (RIA) €38M44 projects HORIZON-RIA · RIA 53%
-
Marie Skłodowska-Curie Actions €16M42 projects HORIZON-TMA-MSCA-DN · HORIZON-TMA-MSCA-DN-ID · HORIZON-TMA-MSCA-SE 22%
-
SME Instrument Phase 2 €5M1 project SME-2 7%
-
EIC Accelerator €4.3M2 projects HORIZON-EIC-ACC-BF 6%
-
Innovation Action (IA) €4.3M10 projects HORIZON-IA · IA 6%
-
Joint Undertaking actions (Horizon Europe) €1.5M2 projects HORIZON-JU-IA · HORIZON-JU-RIA 2%
Notable recent projects
Recent projects with the largest EU contribution to these companies. Links open the project on CORDIS.
-
THANATOS
THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX
Started 2026 Horizon Europe Research and Innovation Action (RIA) Total EU contribution €14M to these companies €4.9M
-
HENIPROTECT
EU-HENIpavirus PROTECTion via inhaled antibody solution
Started 2026 Horizon Europe Research and Innovation Action (RIA) Total EU contribution €16M to these companies €2.3M
-
END2AMR
European Novel Drug research to Address Microbial infections and drug Resistance
Started 2026 Horizon Europe Joint Undertaking actions (Horizon Europe) Total EU contribution €15M to these companies €1.5M
-
KeratOPrinter
Advanced 4D Printing Technologies in Corneal Regeneration: A Pathway to Restored Vision
Started 2025 Horizon Europe Research and Innovation Action (RIA) Total EU contribution €8M to these companies €1.1M
-
NAP4DIVE
Non-Animal Platform for Nanoparticle-Based Delivery across the blood-brain barrier Interface with Vehicle Evolution
Started 2025 Horizon Europe Research and Innovation Action (RIA) Total EU contribution €7.8M to these companies €871k
Classes within Pharmaceutical
| Industry (NACE) | Companies | Projects | To SMEs | EU contribution |
|---|---|---|---|---|
| 21.20 Pharmaceutical Preparations Manufacturing | 31 | 104 | 26% |
€66M
|
| 21.10 Basic Pharmaceutical Products Manufacturing | 7 | 8 | 91% |
€5.9M
|
Funding by country
Get company lists in Claude
Ask Claude for companies by industry, size and region, straight from official European business registers, and export the list as CSV.
Source and method
Source: CORDIS – © European Union, 1994–2026, CC BY 4.0. Data modified: aggregated by EU Company Leads. Project and participant data from CORDIS (Horizon Europe and Horizon 2020 project datasets), licensed under CC BY 4.0.
We count organisations that CORDIS lists as private for-profit companies (activity type PRC) with an EU contribution above zero. Amounts are the EU contribution to those companies, not total project budgets; years are project start years. Industries use NACE Rev. 2.1 from the national business registers of France, Finland, Belgium, Estonia, Sweden and Czech Republic and are only known for companies matched to those registers. Figures computed Nov 17, 2026.